Rule Out of ACS in Primary Care Using a Decision Rule for Chest Pain Including Hs-troponin I POCT (POB HELP)
Primary Purpose
Chest Pain, Myocardial Infarction, Acute Coronary Syndrome
Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Clinical decision rule
Sponsored by
About this trial
This is an interventional diagnostic trial for Chest Pain focused on measuring Chest pain, Primary care, General practice, Myocardial infarction, Troponin, Point of care test
Eligibility Criteria
Inclusion Criteria: ≥18 years of age Acute chest pain Seen by general practitioner Exclusion Criteria: <1 hour since onset of symptoms Inability to speak or understand Dutch Hemodynamic instability
Sites / Locations
- Leiden University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Clinical decision rule
Standard care
Arm Description
Patients in whom the clinical decision rule is used to exclude acute coronary syndrome
Patients in whom the general practitioner decides upon referral following local guidelines.
Outcomes
Primary Outcome Measures
Hospital referral rate for acute chest pain
hospital referral rate for acute chest pain compared between intervention and control group
Hospital referral rate for acute chest pain
hospital referral rate for acute chest pain compared between intervention and control group
Diagnostic accuracy of the clinical decision rule
Diagnostic accuracy (i.e. sensitivity, negative predictive value) for Acute Coronary Syndrome (ACS) and major adverse cardiac events (MACE).
MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Diagnostic accuracy of the clinical decision rule
Diagnostic accuracy (i.e. sensitivity, negative predictive value) for ACS and major adverse cardiac events (MACE)
MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Diagnostic accuracy of the clinical decision rule
Diagnostic accuracy (i.e. sensitivity, negative predictive value) for ACS and major adverse cardiac events (MACE)
MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Secondary Outcome Measures
Cost-effectiveness
A trial-based cost analysis and a cost-utility analysis (costs per QALY, assessed using the EQ-5D-5L questionnaire)
Adherence to the recommendations of the clinical decision rule by general practitioners (GP)
Percentage of general practitioners following and deferring from the clinical decision rule, by comparing the GP's policy with the recommendations of the decision rule.
Patient reassurance measured by the State-Trait Anxiety Inventory
Reassurance of patients, using the State-Trait Anxiety Inventory after the index consultation.
State-Trait Anxiety Inventory: consisting of 40 self-report items on a 4-point Likert scale (min. 20- max. 80 points). Higher scores are correlated with higher levels of anxiety.
Compared between intervention and control group.
Diagnostic accuracy of the gut feeling/ presence of a sense of alarm from general practitioners
Diagnostic accuracy (i.e. sensitivity, negative predictive value) of general practitioner's gut feeling for Acute Coronary Syndrome and major adverse cardiac events (MACE). Using the Gut Feeling Questionnaire (GFC).
The questionnaire consists of 11 items. The items use a 5-point Likert scale: completely disagree to completely agree. Items 1 and 11 are the same and ask the physician about their gut feeling: alarm vs reassuring.
A high score indicates a sense of alarm
(From Barais M, Fossard E, Dany A, et al. Accuracy of the general practitioner's sense of alarm when confronted with dyspnoea and/or chest pain: a prospective observational study. BMJ Open. 2020;10(2):e03434)
Diagnostic accuracy of the HEART-score
Retrospectively for all patient with an ECG available for the occurrence of Acute Coronary Syndrome (ACS) and MACE.
HEART-score assigning 0, 1 or 2 points to patient history, ECG abnormalities, Age, Cardiovascular risk factors and troponin. Lower score (0-3) indicates low risk for acute cardiac event.
MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Subgroup analyses for hospital referral rate for acute chest pain
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
Subgroup analyses for hospital referral rate for acute chest pain
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
Subgroup analyses for diagnostic accuracy of the clinical decision rule
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
For the occurrence of ACS and MACE. MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Subgroup analyses for diagnostic accuracy of the clinical decision rule
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
For the occurrence of ACS and MACE. MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Subgroup analyses for diagnostic accuracy of the clinical decision rule
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
For the occurrence of ACS and MACE. MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Full Information
NCT ID
NCT05827237
First Posted
March 21, 2023
Last Updated
May 23, 2023
Sponsor
Leiden University Medical Center
Collaborators
Maastricht Universitair Medisch Centrum, VieCuri Medical Centre, ZonMw: The Netherlands Organisation for Health Research and Development
1. Study Identification
Unique Protocol Identification Number
NCT05827237
Brief Title
Rule Out of ACS in Primary Care Using a Decision Rule for Chest Pain Including Hs-troponin I POCT
Acronym
POB HELP
Official Title
Primary Care Decision Rule for Chest Pain Using the Marburg Heart Score and Hs-troponin I Point of Care Test to Rule Out Acute Coronary Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 18, 2021 (Actual)
Primary Completion Date
July 1, 2024 (Anticipated)
Study Completion Date
July 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Leiden University Medical Center
Collaborators
Maastricht Universitair Medisch Centrum, VieCuri Medical Centre, ZonMw: The Netherlands Organisation for Health Research and Development
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goal of this clustered, diagnostic randomized controlled trial is to study a clinical decision rule including a high-sensitive troponin I point of care test in patients with chest pain in primary care.
The main questions it aims to answer are:
Can unnecessary referrals to secondary care be reduced by the use of a clinical deci-sion rule in patients with new onset, non-traumatic chest pain in primary care? Compared to current daily practice.
What is the accuracy (sensitivity, negative prediction value) of the clinical decision rule for excluding ACS and MACE at 6 weeks and 6 months?
Detailed Description
This clustered, diagnostic randomized controlled trial will included patients with acute chest pain consulting their general practitioner. Practices in the intervention group will use a clinical decision rule consisting of the Marburg Heart Score and a high-sensitive troponin I point of care test to exclude acute coronary syndrome (ACS) and decide upon referral. Practices in the control group will apply usual care following local guidelines.
An independent endpoint committee consisting of a cardiologist and general practitioner will adjudicate the final diagnosis. Primary endpoints are ACS and Major Adverse Cardiac Events. A delayed reference standard of 6 months will be used.
For high sensitive troponin I measurement, the Siemens Atellica VTLi immunoassay analyser is used.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chest Pain, Myocardial Infarction, Acute Coronary Syndrome
Keywords
Chest pain, Primary care, General practice, Myocardial infarction, Troponin, Point of care test
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A clustered randomized controlled trial in which general practices are randomized to the intervention- or control group in 2:1 ratio.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Clinical decision rule
Arm Type
Experimental
Arm Description
Patients in whom the clinical decision rule is used to exclude acute coronary syndrome
Arm Title
Standard care
Arm Type
No Intervention
Arm Description
Patients in whom the general practitioner decides upon referral following local guidelines.
Intervention Type
Diagnostic Test
Intervention Name(s)
Clinical decision rule
Intervention Description
Clinical decision rule for acute chest pain, consisting of the Marburg Heart Score (5 questions) combined with a high-sensitive troponin I point of care test
Primary Outcome Measure Information:
Title
Hospital referral rate for acute chest pain
Description
hospital referral rate for acute chest pain compared between intervention and control group
Time Frame
24 hours after inclusion
Title
Hospital referral rate for acute chest pain
Description
hospital referral rate for acute chest pain compared between intervention and control group
Time Frame
6 weeks after inclusion
Title
Diagnostic accuracy of the clinical decision rule
Description
Diagnostic accuracy (i.e. sensitivity, negative predictive value) for Acute Coronary Syndrome (ACS) and major adverse cardiac events (MACE).
MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Time Frame
24 hours after inclusion
Title
Diagnostic accuracy of the clinical decision rule
Description
Diagnostic accuracy (i.e. sensitivity, negative predictive value) for ACS and major adverse cardiac events (MACE)
MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Time Frame
6 weeks after inclusion
Title
Diagnostic accuracy of the clinical decision rule
Description
Diagnostic accuracy (i.e. sensitivity, negative predictive value) for ACS and major adverse cardiac events (MACE)
MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Time Frame
6 months after inclusion
Secondary Outcome Measure Information:
Title
Cost-effectiveness
Description
A trial-based cost analysis and a cost-utility analysis (costs per QALY, assessed using the EQ-5D-5L questionnaire)
Time Frame
6 months
Title
Adherence to the recommendations of the clinical decision rule by general practitioners (GP)
Description
Percentage of general practitioners following and deferring from the clinical decision rule, by comparing the GP's policy with the recommendations of the decision rule.
Time Frame
24 hours after inclusion
Title
Patient reassurance measured by the State-Trait Anxiety Inventory
Description
Reassurance of patients, using the State-Trait Anxiety Inventory after the index consultation.
State-Trait Anxiety Inventory: consisting of 40 self-report items on a 4-point Likert scale (min. 20- max. 80 points). Higher scores are correlated with higher levels of anxiety.
Compared between intervention and control group.
Time Frame
1 week after inclusion
Title
Diagnostic accuracy of the gut feeling/ presence of a sense of alarm from general practitioners
Description
Diagnostic accuracy (i.e. sensitivity, negative predictive value) of general practitioner's gut feeling for Acute Coronary Syndrome and major adverse cardiac events (MACE). Using the Gut Feeling Questionnaire (GFC).
The questionnaire consists of 11 items. The items use a 5-point Likert scale: completely disagree to completely agree. Items 1 and 11 are the same and ask the physician about their gut feeling: alarm vs reassuring.
A high score indicates a sense of alarm
(From Barais M, Fossard E, Dany A, et al. Accuracy of the general practitioner's sense of alarm when confronted with dyspnoea and/or chest pain: a prospective observational study. BMJ Open. 2020;10(2):e03434)
Time Frame
6 weeks after inclusion
Title
Diagnostic accuracy of the HEART-score
Description
Retrospectively for all patient with an ECG available for the occurrence of Acute Coronary Syndrome (ACS) and MACE.
HEART-score assigning 0, 1 or 2 points to patient history, ECG abnormalities, Age, Cardiovascular risk factors and troponin. Lower score (0-3) indicates low risk for acute cardiac event.
MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Time Frame
6 weeks after inclusion
Title
Subgroup analyses for hospital referral rate for acute chest pain
Description
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
Time Frame
24 hours after inclusion
Title
Subgroup analyses for hospital referral rate for acute chest pain
Description
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
Time Frame
6 weeks after inclusion
Title
Subgroup analyses for diagnostic accuracy of the clinical decision rule
Description
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
For the occurrence of ACS and MACE. MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Time Frame
24 hours after inclusion
Title
Subgroup analyses for diagnostic accuracy of the clinical decision rule
Description
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
For the occurrence of ACS and MACE. MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Time Frame
6 weeks after inclusion
Title
Subgroup analyses for diagnostic accuracy of the clinical decision rule
Description
Subgroups are classified by
sex
region (Leiden, Maastricht, Venlo)
socio-economic status (using postal-code)
duration of symptoms (<2 hours, 2-6 hours, 6-12 hours, >12 hours, >24 hours)
For the occurrence of ACS and MACE. MACE is defined as a combined endpoint of ACS, percutaneous coronary intervention, coronary artery bypass grafting, coronary angiography revealing procedurally correctable stenosis managed conservatively and all-cause mortality.
Time Frame
6 months after inclusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥18 years of age
Acute chest pain
Seen by general practitioner
Exclusion Criteria:
<1 hour since onset of symptoms
Inability to speak or understand Dutch
Hemodynamic instability
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Simone van den Bulk, MD
Phone
+31615103848
Email
pobhelp@lumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Tobias Bonten, MD PhD
Phone
+31715268479
Email
t.n.bonten@lumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tobias Bonten, MD PhD
Organizational Affiliation
LUMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Leiden University Medical Center
City
Leiden
State/Province
Zuid Holland
ZIP/Postal Code
2300 RC
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simone van den Bulk, MD
Phone
+31615103848
Email
pobhelp@lumc.nl
First Name & Middle Initial & Last Name & Degree
Tobias Bonten, MD, PhD
Phone
+31715268479
Email
t.n.bonten@lumc.nl
First Name & Middle Initial & Last Name & Degree
Tobias Bonten, MD, PhD
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie the results reported in the main article, after deidentification (text, tables, figures and appendices)
IPD Sharing Time Frame
Beginning 3 months and ending 5 years following main article publication
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal.
Links:
URL
http://www.pobhelp.nl
Description
Up to date information about the study for patients and general practitioners (Dutch)
URL
https://trialsearch.who.int/Trial2.aspx?TrialID=NL9525
Description
Original registration on www.NTR.nl before start of the study
Learn more about this trial
Rule Out of ACS in Primary Care Using a Decision Rule for Chest Pain Including Hs-troponin I POCT
We'll reach out to this number within 24 hrs